Literature DB >> 9792165

Immunotherapy for scorpion envenoming in Brazil.

N A Rezende1, C F Amaral, L Freire-Maia.   

Abstract

Using the ELISA we have shown that in rats subcutaneously injected with Tityus serrulatus scorpion venom there is a fast absorption rate, a fast and high distribution of venom to tissues, a great affinity of the venom for the tissues and a slow elimination half-life. Because of these experimental data, i.v. immunotherapy should be given to patients stung by scorpions as soon as possible after hospital admission. The severity of scorpion envenoming is related to plasma venom concentration (ELISA). The high levels of plasma scorpion venom antigens (ELISA) were cleared 1 h after the infusion of antivenom (5-30 ml of Fab2 fragment) and high concentrations of circulating antivenom persisted for at least 24 h, confirming the efficacy of immunotherapy to neutralise circulating venom. Some symptoms (e.g. local pain and vomiting) decreased 1 h after the starting of immunotherapy, whereas the other symptoms disappeared from 12-48 h later. Using our tripartite approach of treating scorpion envenoming (symptomatic measures, support of vital functions and serotherapy), the mortality rate was very low (0.28%).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792165     DOI: 10.1016/s0041-0101(98)00141-x

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  2 in total

1.  Scorpion envenomation among children: clinical manifestations and outcome (analysis of 685 cases).

Authors:  Mabrouk Bahloul; Imen Chabchoub; Anis Chaari; Kamilia Chtara; Hatem Kallel; Hassen Dammak; Hichem Ksibi; Hedi Chelly; Noureddine Rekik; Chokri Ben Hamida; Mounir Bouaziz
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 2.  Venomous Arachnid Diagnostic Assays, Lessons from Past Attempts.

Authors:  Camila Dias-Lopes; Ana Luiza Paiva; Clara Guerra-Duarte; Franck Molina; Liza Felicori
Journal:  Toxins (Basel)       Date:  2018-09-10       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.